Stay updated on NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page.

Latest updates to the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page
- Check6 days agoChange DetectedA new revision tag 'Revision: v3.3.2' is shown and the prior 'Revision: v3.3.1' tag is removed. This is a minor administrative update that does not change study information or user-facing functionality.SummaryDifference0.0%

- Check13 days agoChange DetectedThe Publications section now states that these publications are automatically filled in from PubMed and shows Revision: v3.3.1, replacing the prior note tied to v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedThe general government funding/operating status notice was removed from the page. Study details and links remain unchanged.SummaryDifference0.3%

- Check34 days agoChange DetectedThe REVEAL trial was terminated after Phase 1 results, and Phase 2 will not proceed. The termination was not due to safety concerns.SummaryDifference0.4%

- Check63 days agoChange Detected} , but actually there is a deletions list including 'Cutaneous neuroendocrine carcinoma' which appears to remove a term, and an addition that updates to v3.2.0 along with a government funding notice about operating status. The core page content has been updated (new version number) and a critical notice about government funding and operating status has been added, which affects users' understanding of site reliability. The deletion of a medical term may adjust content relevance but does not outweigh the new status and update information. Overall, the page now communicates current operating status and a new software version, while removing a specific medical term. If a more concise interpretation is needed: the page adds a prominent operating-status notice and a new version, and removes a previously listed medical term.SummaryDifference3%

- Check70 days agoChange DetectedUpdated to revision v3.1.0 and removed the term 'Head and neck squamous cell carcinoma'; overall impact appears minimal unless the page previously discussed that condition.SummaryDifference0.3%

Stay in the know with updates to NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page.